Efficacy of epinastine hydrochloride ophthalmic solution after switched from olopatadine hydrochloride ophthalmic solution in elderly patients with perennial allergic conjunctivitis.

Not Applicable

• Conditions: Perennial allergic conjunctivitis

• Registration Number: JPRN-UMIN000015822
• Lead Sponsor: Inouye Eye Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-12-02
• Study Completion: 2015-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients given immunotherapy (hyposensitization therapy, modulated therapy). 2)Patients with ocular pruritus and hyperemia caused by a disease other than allergic conjunctivitis which will influence drug evaluation. 3)Patients with a history of atopic keratoconjunctivitis, spring catarrh, giant papillary conjunctivitis, corneal herpes, recurrent corneal erosion caused by the frequent occurrence of corneal injury or dry eye. 4)Patients with surgical history in the internal eye (including laser therapy) within 90 days prior to initiation of the clinical research. 5)Patients with possibility taking medicines (including adrenal cortex steroid, anti-allergic agent and immunosuppressive drugs) which affect the efficacy of study drug. However, the use of ophthalmic solutions of adrenal cortex steroid is admitted as needed if there is no improvement in symptoms. 6)Females who are or may be pregnant, or lactating 7)Patients with a history of hypersensitivity to study drug or test material. 8)Patients with severe complications (such as immediate hospitalized care is required) which are identified inappropriate for safety reason. 9)Patients who have any other reasons that causes the study doctor to deem a subject unsuitable for the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement rate of pruritus

Secondary Outcome Measures

Name	Time	Method
Change in scores of subjective symptoms (at visits) Change in scores of objective findings (at visits) Change in scores of fluorescein corneal staining(at visits)